Nexalin Technology (NASDAQ:NXL) is poised to release its quarterly earnings report before the market opens on March 13, 2024. Analysts anticipate the company will report earnings of ($0.12) per share alongside revenues of $0.08 million for the period. This news comes as investors keep a close eye on the company’s performance following a volatile year in the market.
The stock opened at $0.44 on Friday, with a one-year low of $0.37 and a high of $2.57. Currently, Nexalin Technology boasts a market capitalization of $8.14 million, a price-to-earnings ratio of -0.66, and a beta of 4.05. The company’s 50-day moving average stands at $0.57, while the 200-day moving average is $0.89.
Institutional Investors Adjust Positions
Recent activity among institutional investors indicates a growing interest in Nexalin Technology. During the fourth quarter, PEAK6 LLC acquired a new stake valued at $266,000. Additionally, Renaissance Technologies LLC increased its holdings by 119.2%, now owning 122,100 shares valued at $68,000. Geode Capital Management LLC also expanded its stake by 23.4%, resulting in ownership of 150,274 shares worth $84,000 after a recent acquisition.
In the third quarter, Susquehanna International Group LLP purchased a new stake estimated at around $57,000. Currently, institutional investors hold approximately 0.65% of the company’s stock, reflecting a cautious yet strategic approach to investing in Nexalin.
Analyst Ratings Reflect Mixed Sentiment
Analyst ratings for Nexalin Technology reveal mixed sentiments among experts. Recently, Wall Street Zen downgraded the stock from a “hold” to a “sell” rating, while Weiss Ratings maintained a “sell (d-)” rating. Despite this, one analyst has rated the stock as a Buy, balancing the overall outlook. According to data from MarketBeat.com, the average rating for Nexalin Technology is “Hold,” with a consensus price target of $5.00.
Nexalin Technology, Inc. is a U.S.-based medical device firm focused on noninvasive neuromodulation therapies designed for mental health conditions. The company’s flagship product, the Nexalin® medical device, utilizes proprietary alternating current waveforms delivered through forehead-mounted electrodes to modulate neural activity without pharmaceuticals. This innovative approach positions Nexalin within the expanding fields of digital therapeutics and neurostimulation, attracting both interest and scrutiny as it prepares to disclose its financial results.
As the earnings announcement approaches, stakeholders will be closely watching for insights into the company’s financial health and strategic direction in the competitive healthcare landscape.
